LIMA1 and metabolic dysfunction-associated steatotic liver disease: This investigation deepens our understanding of the role of LIMA1 in the progression of MASLD and proposes a potential therapeutic strategy for MASH by targeting LIMA1 O‐GlcNAcylation.